Deslorelin for Horses: Uses, Dosing & Side Effects

This information is for educational purposes only. Never give your pet any medication without your veterinarian's guidance. Dosing, frequency, and safety depend on your pet's specific health profile.

Deslorelin is a synthetic gonadotropin-releasing hormone (GnRH) agonist used in equine reproduction. In U.S. practice, it is most commonly used in mares to help induce ovulation within a predictable window, which can make breeding management more efficient when timing matters.

The currently recognized U.S. equine product is deslorelin acetate injection. It is given by your vet as an intramuscular injection after confirming that the mare is in estrus and has an appropriately sized follicle on reproductive exam, usually with palpation and ultrasound.

Deslorelin works by triggering a hormone surge that encourages the ovary to release a mature egg. That is why it is not a medication pet parents should use on their own. Success depends on the mare being at the right stage of her cycle, and on careful monitoring before and after treatment.

In horses, deslorelin is used primarily for timed ovulation in cyclic estrous mares. Merck notes that mares with mature preovulatory follicles can ovulate within about 48 hours, and often around 36 to 42 hours after injectable deslorelin. That timing can help your vet coordinate natural cover, shipped semen, or other breeding plans more precisely.

Your vet may recommend deslorelin when a mare has a 30 to 40 mm follicle and is showing signs of estrus. The labeled U.S. indication is to induce ovulation within 48 hours in these mares. This can reduce guesswork and may decrease the number of repeat reproductive exams needed during a breeding cycle.

Historically, slow-release implants were also used in mares. However, implant formulations have been associated in some studies and references with delayed return to normal cycling or prolonged interovulatory intervals in some mares, which is one reason many equine reproduction programs now favor injectable protocols when available.

Deslorelin dosing in horses should be determined by your vet based on the mare's reproductive status. For the labeled U.S. injectable product, the usual dose is 1 mL intramuscularly once per estrus cycle, which provides 1.8 mg of deslorelin acetate. The mare should be confirmed to be in estrus and to have at least one ovarian follicle between 30 and 40 mm before treatment.

The goal is to give the medication about 48 hours before the desired ovulation window. In practice, your vet usually confirms follicle size and uterine edema by ultrasound, then administers the injection into the neck musculature. Only one 1 mL dose per mare during a given estrus is recommended on the product labeling.

Timing matters more than body weight for this medication. A mare treated too early, too late, or when she is not truly in estrus may not respond as expected. That is why deslorelin is typically part of a broader breeding plan that may include serial ultrasound exams, semen timing, and follow-up confirmation of ovulation.

Most mares tolerate injectable deslorelin well, but mild to moderate injection-site swelling is the most commonly reported adverse effect. In safety data for the labeled injectable product, these swellings were usually temporary and resolved within a few days in mares receiving the standard dose.

Less commonly, horses may show signs of a hypersensitivity-type reaction. In higher-dose safety testing, one mare developed moderate tremors and hives several hours after treatment. If your horse develops hives, shaking, facial swelling, breathing changes, or sudden distress after an injection, see your vet immediately.

Older implant-based protocols have also been associated with delayed cycling or longer interovulatory intervals in some mares. That concern is more relevant to slow-release implant use than to the currently labeled U.S. injectable product, but it is still worth discussing with your vet if your mare has a history of irregular cycles or if you are planning repeated reproductive treatments.

There is limited published interaction data specific to horses, so your vet should review all reproductive hormones, supplements, and recent medications before using deslorelin. In breeding practice, deslorelin is often used alongside other reproductive management tools, such as prostaglandins or progesterone-based protocols, but the exact sequence and timing matter.

Because deslorelin acts on the reproductive hormone axis, it may have additive or altering effects when combined with other drugs that influence estrus, ovulation, or luteal function. That does not always mean the combination is unsafe. It means the protocol should be intentional and monitored.

Be sure to tell your vet if your mare has received human chorionic gonadotropin (hCG), altrenogest, prostaglandins, compounded reproductive hormones, or any recent injectable medications. Also mention prior reactions to hormone products. If your mare is intended for competition, ask your vet whether any treatment timing could affect event rules or withdrawal guidance.